# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Equal-Weight and raises the price targ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of ...
Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 p...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...